◎香港のセンターで最先端技術によるがん患者治療

AsiaNet 52369

共同JBN0261（2013.3.14）

【サニーベール（米カリフォルニア州）2013年3月14 日PRN＝共同JBN】アキュレイ社（Accuray Incorporated、ナスダック：ARAY）は14日、サイバーナイフ（登録商標）ラジオサージェリーシステムとトモセラピー（登録商標）システムによる治療を現地で提供する初のセンターである香港アドベンティスト腫瘍センターが先週公式の開所式を行ったと発表した。香港アドベンティスト腫瘍センターは、両システムを使えるように設計された新築のがんセンターである。トモセラピーシステムは昨年末に設置され、サイバーナイフ・システムは2006年9月に設置された。

香港アドベンティスト腫瘍科センターの臨床ディレクターであるスティーブン・ロー博士は「放射線治療計画、実施のための最も柔軟性のある精密なソリューションを使って広範な患者に個別化治療を提供できるのはうれしい。サイバーナイフ、トモセラピー両システムによって、センターの臨床医は初期で局所的な疾患に対する高精密度放射線手術から体全体のより進行した疾患向けの画像誘導による強度変調放射線療法（IG-IMRT）まで、専門的な治療を行うことができる」と語っている。

アキュレイのライオネル・ハジャジェバEIMEA（欧州、インド、中東、アジア）ゼネラルマネジャー兼国際ビジネス担当上級副社長は「わが社の2つの先端的ソリューションであるサイバーナイフ、トモセラピー両システムは、腫瘍部門のすべての放射線外部照射のニーズを満たし、最適な治療結果の追求に使える柔軟性のある個別化治療オプションを臨床医に提供する。アキュレイの多機能システムを採用すればあらゆる範囲の放射線腫瘍患者に役立つ包括的な治療ソリューションを提供できることが一貫して証明されている」と述べている。

香港アドベンティスト腫瘍センターについての詳しい情報はhttp://www.hkah.org.hk/new/eng/service_tumor_center03.php#cへ。

▽アキュレイについて

アキュレイ社（Accuray Incorporated、ナスダック：ARAY）は放射線腫瘍学の企業で、患者のより長く、より良い生活の支援を目標とし、治療標準となる患者ごとの革新的な治療ソリューションを開発、製造、販売している。同社の先端的技術はあらゆる範囲の放射線療法・放射線手術治療を提供することができる。

ソース：Accuray Incorporated

▽問い合わせ先

Rebecca Phillips

Public Relations Manager

Accuray

+1-408-716-4773

rphillips@accuray.com;

Kaman Ng

Manager

Marketing Communications (APAC)

+852-2247-8622

kng@accuray.com

Takako Takeda

Marketing Director (Japan)

+81-3-6265-1526

ttakeda@accuray.com

First Center in Hong Kong Treats Patients with CyberKnife(R) and TomoTherapy(R) Systems

PR52369

SUNNYVALE, Calif., Mar. 14, 2013 /PRN=KYODO JBN/ --

              Hong Kong Adventist Oncology Center Offers Full

       Spectrum of Disease Treatment with State-of-the-art Technologies

    Accuray Incorporated (Nasdaq: ARAY), announced today that Hong Kong

Adventist Oncology Center, the first center locally to offer both the

CyberKnife(R) Robotic Radiosurgery and TomoTherapy(R) Systems, hosted its

official opening ceremony last week. Hong Kong Adventist Oncology Center is a

newly built cancer center that was designed to accommodate both systems. Their

TomoTherapy System was installed late last year and their CyberKnife System was

installed in September 2006.

    "We are pleased to offer the most flexible, precise solutions for radiation

treatment planning and delivery that enable us to deliver personalized

treatments to a wide range of patients," said Dr. Stephen Law, clinical

director of Hong Kong Adventist Oncology Center. "The CyberKnife and

TomoTherapy Systems allow our clinicians to create specialized treatments

ranging from high-precision radiosurgery for early-stage and localized disease

to image-guided, intensity-modulated radiation therapy (IG-IMRT) for more

advanced disease throughout the body."

    "Our two leading-edge treatment solutions - the CyberKnife and the

TomoTherapy Systems - satisfy all the external beam radiation delivery needs of

an oncology department and give clinicians flexible, individualized treatment

options to use in their pursuit of optimal treatment outcomes." said Lionel

Hadjadjeba, general manager EIMEA and senior vice president of International

Business at Accuray. "The adoption of Accuray's versatile systems are

constantly proven to provide comprehensive treatment solutions that serve the

full spectrum of radiation oncology patients."

    For more information of Hong Kong Adventist Oncology Center, please visit

http://www.hkah.org.hk/new/eng/service_tumor_center03.php#c     

    About Accuray

    Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that

develops, manufactures and sells personalized, innovative treatment solutions

that set the standard of care with the aim of helping patients live longer,

better lives. The Company's leading-edge technologies deliver the full range of

radiation therapy and radiosurgery treatments.

    Safe Harbor Statement

    Statements made in this press release that are not statements of historical

fact are forward-looking statements and are subject to the "safe harbor"

provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements in this press release relate, but are not limited,

to clinical applications, clinical results, patient outcomes, and the Company's

leadership position in radiation oncology innovation. Forward-looking

statements are subject to risks and uncertainties that could cause actual

results to differ materially from expectations, including risks detailed from

time to time under the heading "Risk Factors" in the company's report on Form

10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on

November 8, 2012 & February 6, 2013, and as updated periodically by our other

filings. Forward-looking statements speak only as of the date the statements

are made and are based on information available to the Company at the time

those statements are made and/or management's good faith belief as of that time

with respect to future events. The Company assumes no obligation to update

forward-looking statements to reflect actual performance or results, changes in

assumptions or changes in other factors affecting forward-looking information,

except to the extent required by applicable securities laws.  Accordingly,

investors should not place undue reliance on any forward-looking statements.

    SOURCE: Accuray Incorporated

   CONTACT: Rebecca Phillips

            Public Relations Manager

            Accuray

            +1-408-716-4773

            rphillips@accuray.com;

            Kaman Ng

            Manager

            Marketing Communications (APAC)

            +852-2247-8622

            kng@accuray.com